OncoMatch/Clinical Trials/NCT04505254
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
Is NCT04505254 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Obinutuzumab and Acalabrutinib for chronic lymphocytic leukemia.
Treatment: Acalabrutinib · Obinutuzumab — This phase II trial investigates the how well acalabrutinib and obinutuzumab work in treating patients with chronic lymphocytic leukemia (CLL). Acalabrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving acalabrutinib and obinutuzumab may help to control disease progression in CLL patients who have not received treatment for CLL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: cll/sll treatment
Lab requirements
Blood counts
Absolute neutrophil count ≥ 500/μL (unless disease-related); platelet count ≥ 30,000/μL at screening
Kidney function
Estimated creatinine clearance (CrCl) > 30 mL/min, unless disease related
Liver function
Total bilirubin ≤ 1.5 x ULN except for Gilbert's disease; ALT ≤ 2.5 x ULN
Adequate renal and hepatic function as indicated by all of the following: Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) except for patients with bilirubin elevation due to Gilbert's disease who will be allowed to participate; ALT ≤ 2.5 x ULN; estimated creatinine clearance (CrCl) > 30 mL/min, as calculated by the Cockcroft-Gault equation unless disease related; severe hematopoietic insufficiency as defined by an absolute neutrophil count of less than 500/μL, unless disease-related, and/or a platelet count of less than 30,000/μL at time of screening for this protocol.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify